19.91 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||15.00 x 800|
|Ask||19.95 x 800|
|Day's range||18.72 - 20.01|
|52-week range||6.95 - 31.69|
|Beta (5Y monthly)||2.18|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Every investor in Cue Biopharma, Inc. (NASDAQ:CUE) should be aware of the most powerful shareholder groups. Large...
Greetings, and welcome to Cue Biopharma first-quarter 2020 earnings call. It is now my pleasure to introduce your host Ashley Robinson, investor relations. This is Ashley from LifeSci Advisors, and thank you for joining us on today's investor and analyst update call.
Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...
Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma
Zacks.com featured highlights include: Independent Bank, HarborOne, Horizon Technology Finance and Cue Biopharma
Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.
If you own shares in Cue Biopharma, Inc. (NASDAQ:CUE) then it's worth thinking about how it contributes to the...
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
Cue Biopharma, Inc. (CUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...